Capricor Therapeutics
CAPR
107 hedge funds and large institutions have $137M invested in Capricor Therapeutics in 2025 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 41 increasing their positions, 37 reducing their positions, and 29 closing their positions.
11% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 37
10.03% less ownership
Funds ownership: 40.11% → 30.08% (-10%)
11% less funds holding
Funds holding: 120 → 107 (-13)
12% less call options, than puts
Call options by funds: $61.2M | Put options by funds: $69.8M
22% less capital invested
Capital invested by funds: $174M → $137M (-$37.4M)
41% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$1.88M |
| 2 |
National Bank of Canada
Montreal,
Quebec, Canada
|
+$1.78M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$1.65M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$847K |
| 5 |
HSA
HBK Sorce Advisory
Erie,
Pennsylvania
|
+$822K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$23.3M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$5.15M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$4.39M |
| 4 |
State Street
Boston,
Massachusetts
|
-$3.97M |
| 5 |
Goldman Sachs
New York
|
-$3.58M |
CAPR Hedge Fund Activity: Q2 2025 in Review
107 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Capricor Therapeutics (CAPR) for Q2 2025, worth a combined $137M — down 22% from $174M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of CAPR and 17 opened new positions — a net loss of 12 holders — while 37 trimmed existing stakes and 41 added.
The largest buyer was JP Morgan Chase, adding an estimated $1.88M. The largest seller was Farallon Capital Management, cutting an estimated $23.3M.
- 107 institutional investors held Capricor Therapeutics (CAPR) as of Q2 2025, down from 120 in Q1 2025.
- Funds reported $137M of Capricor Therapeutics stock for Q2 2025, down 22% quarter-over-quarter.
- 17 funds opened new Capricor Therapeutics positions in Q2 2025 and 29 closed out, a net change of -12 holders.
- The largest Capricor Therapeutics buyer in Q2 2025 was JP Morgan Chase, an estimated $1.88M added.
- The largest Capricor Therapeutics seller in Q2 2025 was Farallon Capital Management, an estimated $23.3M sold.
Based on aggregated 13F filings for Q2 2025.